Ikaros (IKZF1) Human shRNA Lentiviral Particle (Locus ID 10320)
CAT#: TL308127V
IKZF1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
货期*
详询
规格
Cited in 10 publications. |
经常一起买 (3)
Specifications
Product Data | |
Product Name | Ikaros (IKZF1) Human shRNA Lentiviral Particle (Locus ID 10320) |
Locus ID | 10320 |
Synonyms | CVID13; Hs.54452; IK1; IKAROS; LyF-1; LYF1; PPP1R92; PRO0758; ZNFN1A1 |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_001220765, NM_001220766, NM_001220767, NM_001220768, NM_001220769, NM_001220770, NM_001220771, NM_001220772, NM_001220773, NM_001220774, NM_001220775, NM_001220776, NM_001291837, NM_001291838, NM_001291839, NM_001291840, NM_001291841, NM_001291842, NM_001291843, NM_001291844, NM_001291845, NM_001291846, NM_001291847, NM_006060, NM_006060.1, NM_006060.2, NM_006060.3, NM_006060.4, NM_006060.5, NM_001220772.1, NM_001220776.1, NM_001220775.1, NM_001220774.1, NM_001220773.1, NM_001220771.1, NM_001220771.2, NM_001220770.1, NM_001220770.2, NM_001220769.1, NM_001220767.1, NM_001220767.2, NM_001220766.1, NM_001220768.1, NM_001220768.2, NM_001220765.1, NM_001220765.2, NM_001291846.1, NM_001291847.1, NM_001291845.1, NM_001291840.1, NM_001291844.1, NM_001291843.1, NM_001291842.1, NM_001291841.1, NM_001291839.1, NM_001291838.1, NM_001291837.1, BC018349, BC064594, BC075820, BM148203, NM_001291837.2, NM_001291838.2, NM_006060.6, NM_001291839.2, NM_001220765.3, NM_001291847.2, NM_001291846.2, NM_001291845.2 |
Summary | This gene encodes a transcription factor that belongs to the family of zinc-finger DNA-binding proteins associated with chromatin remodeling. The expression of this protein is restricted to the fetal and adult hemo-lymphopoietic system, and it functions as a regulator of lymphocyte differentiation. Several alternatively spliced transcript variants encoding different isoforms have been described for this gene. Most isoforms share a common C-terminal domain, which contains two zinc finger motifs that are required for hetero- or homo-dimerization, and for interactions with other proteins. The isoforms, however, differ in the number of N-terminal zinc finger motifs that bind DNA and in nuclear localization signal presence, resulting in members with and without DNA-binding properties. Only a few isoforms contain the requisite three or more N-terminal zinc motifs that confer high affinity binding to a specific core DNA sequence element in the promoters of target genes. The non-DNA-binding isoforms are largely found in the cytoplasm, and are thought to function as dominant-negative factors. Overexpression of some dominant-negative isoforms have been associated with B-cell malignancies, such as acute lymphoblastic leukemia (ALL). [provided by RefSeq, May 2014] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (10)
The use of this RNAi has been cited in the following citations: |
---|
Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2
,null,
International Journal of Molecular Sciences
,PubMed ID 33467550
[IKZF1]
|
RAG1 high expression associated with IKZF1 dysfunction in adult B-cell acute lymphoblastic leukemia
,null,
Journal of Cancer
,PubMed ID 31333801
[IKZF1]
|
Welcome to the 10th volume of Epigenomics.
,null,
Epigenomics
,PubMed ID 29192515
[IKZF1]
|
Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia
,null,
Oncogenesis
,PubMed ID 30420689
[IKZF1]
|
Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia
,null,
Epigenomics
,PubMed ID 28994305
[IKZF1]
|
Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia
,null,
Scientific Reports
,PubMed ID 27885263
[IKZF1]
|
High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement
,null,
Oncotarget
,PubMed ID 27391346
[IKZF1]
|
Co-existence of IL7R high and SH2B3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction
,null,
Oncotarget
,PubMed ID 27322554
[IKZF1]
|
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia *
,null,
The Journal of Biological Chemistry
,PubMed ID 26655717
[IKZF1]
|
Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia
,null,
Oncotarget
,PubMed ID 26517351
[IKZF1]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...